Quadruplet GvHD Prophylaxis with Vedolizumab, Post‑Transplant Cyclophosphamide, Abatacept, and Calcineurin Inhibitors in Adult Allo‑HSCT: A Prospective Single‑Center Study (ICBMT 2026) - Oct 8, 2026 - Abstract #PP06‑06; "The incorporation of vedolizumab into a combination GVHD prophylaxis regimen was associated with a low incidence of severe gastrointestinal aGVHD and a favorable safety profile, without compromising engraftment. These findings support the potential role of α4β7 integrin blockade as a targeted preventive approach and justify further investigation in randomized clinical trials Keywords: GVHD Prophylaxis, Allo‑HSCT, Vedolizumab"
Clinical • Post-transplantation • Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Transplantation
|
|
Artur Yunusov 1; Matvey Bulusov 1; Lev Butaev 1; Anastasia Nekrasova 1; Sergey Shalaev 1; Evdokia Urnova 1; Vera Zherebtsova 1; Anton Subora 1; Irina Zikunova 1; Yulia Kruchinkina 1; Daria Kisilichina 1; Arina Lugovaya 1; Victoria Skurikhina 1; Vadim Ptushkin 1
|